Aquestive Therapeutics Inc.
| NASDAQ: AQST |
| Healthcare / Biotechnology / USA |
| 3.58 | -0.1800 | -4.79% | Vol 203.72K | 1Y Perf -30.33% |
| Jul 23rd, 2021 16:00 DELAYED |
| BID | 3.62 | ASK | 3.74 | ||
| Open | 3.77 | Previous Close | 3.76 | ||
| Pre-Market | - | After-Market | - | ||
| - - | - -% |
| Target Price | 17.00 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 374.86 | Finscreener Ranking | ★★★ 49.14 | |
| Insiders Trans % 3/6/12 mo. | -/-100/-100 | Value Ranking | ★+ 45.26 | |
| Insiders Value % 3/6/12 mo. | -/-100/-100 | Growth Ranking | ★★+ 47.70 | |
| Insiders Shares Cnt. % 3/6/12 mo. | -/-100/-100 | Income Ranking | — - | |
| Market Cap | 131.00M | Earnings Rating | Buy | |
| Price Range Ratio 52W % | 6.51 | Earnings Date | 3rd Aug 2021 |
Today's Price Range 3.553.77 | 52W Range 3.179.47 |
Summary:
Sell
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Sell |
| Performance | |||
|---|---|---|---|
| 1 Week | 7.83% | ||
| 1 Month | -17.13% | ||
| 3 Months | -12.90% | ||
| 6 Months | -36.86% | ||
| 1 Year | -30.33% | ||
| 3 Years | - | ||
| 5 Years | - | ||
| 10 Years | - |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | 83.42 | |||
ROE last 12 Months | 148.50 | |||
ROA (5Y Avg) | -65.43 | |||
ROA last 12 Months | -85.32 | |||
ROC (5Y Avg) | - | |||
ROC last 12 Months | -107.70 | |||
Return on invested Capital Q | - | |||
Return on invested Capital Y | -107.70 | |||
Assets Turnover | 0.20 | |||
Receivables Turnover | 0.90 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -2.10 | ||||
| 14.15 | ||||
| 4.58 | ||||
| 38.20 | ||||
| -3.30 | ||||
| -1.34 | ||||
| -2.34 | ||||
| -1.42 | ||||
| 135.47M | ||||
| Forward PE | -2.91 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 1.90 | ||||
| 2.20 | ||||
| - | ||||
| - | ||||
| -2.30 | ||||
| Leverage Ratio | -1.20 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 75.00 | ||||
| -77.80 | ||||
| -71.00 | ||||
| -74.10 | ||||
| -91.51 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 26.53M | ||||
| 0.73 | ||||
| -19.37 | ||||
| - |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q01 2021 | -0.44 | -0.41 | 6.82 |
| Q04 2020 | -0.46 | -0.60 | -30.43 |
| Q03 2020 | -0.50 | -0.49 | 2.00 |
| Q02 2020 | -0.43 | -0.07 | 83.72 |
| Q01 2020 | -0.52 | -0.49 | 5.77 |
| Q04 2019 | -0.45 | -0.48 | -6.67 |
| Q03 2019 | -0.78 | -0.54 | 30.77 |
| Q02 2019 | -0.67 | -0.82 | -22.39 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 6/2021 QR | -0.42 | 2.33 | Positive |
| 9/2021 QR | -0.44 | 4.35 | Positive |
| 12/2021 FY | -1.70 | 2.86 | Positive |
| 12/2022 FY | -1.14 | -3.64 | Negative |
| Next Report Date | 3rd Aug 2021 |
| Estimated EPS Next Report | -0.42 |
| Estimates Count | 2 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 203.72K |
| Shares Outstanding | 36.59M |
| Trades Count | 1.43K |
| Dollar Volume | 4.88M |
| Avg. Volume | 769.75K |
| Avg. Weekly Volume | 524.30K |
| Avg. Monthly Volume | 643.28K |
| Avg. Quarterly Volume | 583.51K |
Aquestive Therapeutics Inc. (NASDAQ: AQST) stock closed at 3.58 per share at the end of the most recent trading day (a -4.79% change compared to the prior day closing price) with a volume of 204.39K shares and market capitalization of 131.00M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 232 people. Aquestive Therapeutics Inc. CEO is Keith J. Kendall.
The one-year performance of Aquestive Therapeutics Inc. stock is -30.33%, while year-to-date (YTD) performance is -33.08%. AQST stock has a five-year performance of %. Its 52-week range is between 3.17 and 9.47, which gives AQST stock a 52-week price range ratio of 6.51%
Aquestive Therapeutics Inc. currently has a PE ratio of -2.10, a price-to-book (PB) ratio of 14.15, a price-to-sale (PS) ratio of 4.58, a price to cashflow ratio of 38.20, a PEG ratio of 2.32, a ROA of -85.32%, a ROC of -107.70% and a ROE of 148.50%. The company’s profit margin is -91.51%, its EBITDA margin is -71.00%, and its revenue ttm is $26.53 Million , which makes it $0.73 revenue per share.
Of the last four earnings reports from Aquestive Therapeutics Inc., there were 3 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $-0.42 for the next earnings report. Aquestive Therapeutics Inc.’s next earnings report date is 03rd Aug 2021.
The consensus rating of Wall Street analysts for Aquestive Therapeutics Inc. is Strong Buy (1), with a target price of $17, which is +374.86% compared to the current price. The earnings rating for Aquestive Therapeutics Inc. stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Aquestive Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Aquestive Therapeutics Inc. has a Sell technical analysis rating based on Technical Indicators (ADX : 18.96, ATR14 : 0.22, CCI20 : -29.18, Chaikin Money Flow : -0.23, MACD : -0.08, Money Flow Index : 50.15, ROC : 1.99, RSI : 44.46, STOCH (14,3) : 47.37, STOCH RSI : 0.64, UO : 52.18, Williams %R : -52.63), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Aquestive Therapeutics Inc. in the last 12-months were: A. Mark Schobel (Sold 75 792 shares of value $501 398 ), John T. Maxwell (Sold 3 000 shares of value $24 000 )
Aquestive Therapeutics Inc.
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. The product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS). Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, and Zuplenz. The products pipeline includes Exservan Oral Film, Libervant Buccal Film, AQST-119, AQST-108, and AQST-305.
CEO: Keith J. Kendall
Telephone: +1 908 941-1900
Address: 30 Technology Drive, Warren 07059, NJ, US
Number of employees: 232
